Tackling tumours

Czyzewski, Andrew
April 2011
Engineer (00137758);4/25/2011, Vol. 296 Issue 7815, p18
No abstract available.


Related Articles

  • Two antibodies for the price of one. DeFrancesco, Laura // Nature Biotechnology;Dec2011, Vol. 29 Issue 12, p1101 

    The article reports that researchers at Genentech have created two-in-one antibodies that target two common cancer targets through the same binding site.

  • Targeting a killer gene.  // Newsweek;6/1/1998, Vol. 131 Issue 22, p59 

    Focuses on Herceptin, a genetically engineered antibody developed at the University of California at Los Angeles' Jonsson Cancer Center. How Herceptin works in breast cancer; The drug needing approval from the United States Food and Drug Administration.

  • Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. Kanz, Bridgette A.; Pollack, Megan H.; Johnpulle, Romany; Puzanov, Igor; Horn, Leora; Morgans, Alicia; Sosman, Jeffrey A.; Rapisuwon, Suthee; Conry, R. Martin; Eroglu, Zeynep; Johnson, Douglas B. // Journal for ImmunoTherapy of Cancer;10/18/2016, Vol. 4, p1 

    Background: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not...

  • Monoclonal Antibodies for Treating Cancer. Dillman, Robert O. // Annals of Internal Medicine;10/1/89, Vol. 111 Issue 7, p592 

    Discusses a study which assessed the status of in-vivo use of monoclonal antibodies for treating cancer. Obstacles to systematic cancer therapy; Potential therapeutic applications of monoclonal antibodies; Clinical trials of monoclonal antibodies used alone.

  • Immunotherapy: A killer combination. Bird, Lucy // Nature Reviews Immunology;Apr2012, Vol. 12 Issue 4, p231 

    The article discusses the research study by H. E. Kohrt and colleagues in a 2012 issue of the "Journal of Clinical Investigation" which shows the efficacy of the antibody trastuzumab and a natural killer (NK) cell-activating antibody in treating breast cancer.

  • The Notch ligand Jagged1 as a target for anti-tumor therapy. Li, Demin; Masiero, Massimo; Banham, Alison H.; Harris, Adrian L. // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    The Notch pathway is increasingly attracting attention as a source of therapeutic targets for cancer. Ligand-induced Notch signaling has been implicated in various aspects of cancer biology; as a consequence, pan-Notch inhibitors and therapeutic antibodies targeting one or more of the Notch...

  • Killing Cancer From The Inside. HURLEY, DAN // Discover;Jan/Feb2012, Vol. 33 Issue 1, p53 

    The article reports on cancer therapies that do not damage healthy cells, including engineered antibodies that target cancer cell proteins, molecular logic circuits helping to create killer proteins for specific cancers, and a molecular switch to activate chemotherapy drugs within cancer cells.

  • The peculiarities of anti-HSP60 antibodies at thyrod cancer progression. Sidorik, L.; Yakovenko, L.; Kroupskaya, I.; Roiuk, M.; Chornyy, S.; Tsisarenko, A.; Tykhonkova, I.; Pogribnyy, P.; Gurtovyy, V.; Usenko, V. // Biopolymers & Cell;2015 Suppl. 5, p27 

    Background. The study of anti-Hsp60 antibodies levels in several tumors is a topic of growing interest. It was demonstrated that levels of circulating anti-Hsp60 antibodies and Hsp60 could be used as biomarkers for carcinogenesis, and prognosis factor for survival and treatment susceptibility....

  • Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Ferrari, Francesca; Bellone, Stefania; Black, Jonathan; Schwab, Carlton L.; Lopez, Salvatore; Cocco, Emiliano; Bonazzoli, Elena; Predolini, Federica; Menderes, Gulden; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; Azodi, Masoud; Schwartz, Peter E.; Santin, Alessandro D. // Journal of Experimental & Clinical Cancer Research (17569966);10/17/2015, Vol. 34, p1 

    Background: Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely poor prognosis. We evaluated the expression levels of EpCAM and the in vitro activity of solitomab, a bispecific single-chain antibody construct which targets...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics